Dual Gut Microbiota‐Dependent Mechanisms Underlying the Anti‐Atherosclerotic Effect of Tilianin
Abstract
ABSTRACT Tilianin (Til), a flavonoid from Dracocephalum moldavica L. and Agastache species, exerts potent anti‐atherosclerotic effects via gut microbiota‐mediated mechanisms. In atherosclerotic mice, Til dose‐dependently reduced plaque burden and enhanced plaque stability by reducing necrotic cores and increasing collagen. Til also improved lipid profiles, attenuated inflammation, and lowered trimethylamine N‐oxide (TMAO) levels, accompanied by microbiota remodeling—specifically, enhancing α‐diversity and enriching Akkermansia muciniphila. Fecal microbiota transplantation from Til‐treated donors successfully transferred these protective phenotypes. Conversely, antibiotic‐induced microbiota depletion selectively abrogated the plaque‐stabilizing arm of Til's action, leaving its effect on overall plaque burden intact, despite maximized TMAO reduction and increased systemic exposure. This “antibiotic paradox” stemmed from short‐chain fatty acid (SCFA) depletion and intestinal barrier breakdown (decreased ZO‐1/occludin), triggering metabolic endotoxemia (elevated LPS). Mechanistically, Til directly inhibits microbial trimethylamine monooxygenase (TMM) with nanomolar potency (IC50 = 18.78 nM), blocking local TMA‐to‐TMAO conversion. Overall, Til's lipid‐lowering, anti‐inflammatory, and antioxidant activities in vivo are gated by a pivotal microbiota–metabolite–barrier axis, acting through dual enzymatic inhibition and homeostasis maintenance, offering novel insights for flavonoid‐based multi‐target atherosclerosis therapies.